Vericel (NASDAQ:VCEL) Releases Earnings Results, Beats Expectations By $0.21 EPS

Vericel (NASDAQ:VCEL) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21, Zacks reports. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The company had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. During the same quarter in the previous year, the business earned $0.10 EPS. Vericel’s revenue was up 26.5% compared to the same quarter last year.

Here are the key takeaways from Vericel’s conference call:

• Vericel reported third-quarter revenue of $85.4 million, up 26%, and raised 2026 revenue guidance to $344 million–$346 million after results exceeded expectations. The company also raised adjusted EBITDA margin guidance to approximately 28%.
• MACI revenue grew 21% to a record $67.4 million, with records for biopsies, implants, and participating surgeons; October also brought the strongest biopsy month since launch. Management cited sales-force expansion, deeper surgeon engagement, and MACI Arthro adoption as growth drivers, while noting that biopsies convert to procedures over time.
• Burn-care revenue reached a record $18 million, up 52%, with record quarterly revenue for both Epicel and commercial NexoBrid. Management attributed Epicel’s strength mainly to commercial execution, while acknowledging that burn-care results can be variable and that the number of severe burns is outside the company’s control.
• Profitability and cash generation strengthened: adjusted EBITDA rose 48% to $25.2 million, free cash flow was $16 million, and the company ended the quarter with $236 million in cash and investments and no debt. Vericel said it remains on track with its longer-term targets, while continuing investments in growth and exploring both share repurchases and business development.

Vericel Stock Up 13.9%

NASDAQ:VCEL traded up $6.30 during midday trading on Thursday, hitting $51.78. The stock had a trading volume of 2,682,362 shares, compared to its average volume of 594,165. The stock has a 50-day moving average of $40.56 and a 200 day moving average of $38.73. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of 110.17 and a beta of 1.08. Vericel has a one year low of $28.95 and a one year high of $55.60.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Vericel in a research note on Tuesday, July 28th. TD Cowen boosted their target price on shares of Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Truist Financial cut their price target on shares of Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. Finally, Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Vericel currently has an average rating of “Moderate Buy” and an average price target of $57.20.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, above analysts’ estimate of about $78 million. Earnings of $0.27 per share also topped the roughly $0.06 consensus, and net income increased 179% to $14.2 million. Reports highlighted record MACI sales as a key growth driver. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised full-year 2026 revenue guidance to $344 million–$346 million, above the approximately $336 million analyst estimate, and lifted its adjusted EBITDA margin outlook to 28%. The higher forecast reinforces expectations for continued growth. Vericel raises 2026 revenue outlook
• Neutral Sentiment: The earnings call transcript may provide further detail on sales drivers and management’s outlook, but the headlines provided do not identify additional material developments. Vericel Q3 2026 earnings call transcript
• Negative Sentiment: A separate analysis argues that VCEL may look overvalued relative to its earnings support, a potential risk if investors question whether its recent growth and improved outlook justify the stock’s valuation. Valuation analysis of Vericel

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.